Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
17 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to NovaBridge Biosciences’s names, not what it holds today.
Patents granted
17
17 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and 1 in 2023
Applications published
31
2 of them in 2025
Names they are printed under
4
a subsidiary, a former name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals7
Biotechnology4
Analysis of biological materials1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
I-MAB BIOPHARMA US LIMITED a subsidiary
US, as the owner printed on each patent
6 publishedI-Mab Biopharma US Limited a subsidiary
named as the applicant on its applications, in US
14 publishedI-MAB a former name
named as the applicant on its applications, in KY. 1 more under the same name are not counted (printed in CN)
10 publishedI-MAB a former name
KY, as the owner printed on each patent
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jan 14, 2025 | 12,195,538 | Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof | Biotechnology | I-MAB BIOPHARMA US LIMITED |
| Nov 19, 2024 | 12,145,982 | Anti-CXCL13 antibodies for treating autoimmune diseases and cancer | Pharmaceuticals | I-MAB BIOPHARMA US LIMITED |
| Sep 17, 2024 | 12,091,467 | CD47 monoclonal antibodies and uses thereof | Pharmaceuticals | I-MAB BIOPHARMA US LIMITED |
| Mar 28, 2023 | 11,613,577 | Anti-CD73 antibodies and uses thereof | Pharmaceuticals | I-MAB |
| Aug 2, 2022 | 11,401,331 | Anti-PD-L1 antibody and IL-7 fusions | Biotechnology | I-MAB BIOPHARMA US LIMITED |
| Mar 1, 2022 | 11,261,259 | Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof | Biotechnology | I-MAB BIOPHARMA US LIMITED |
| Jan 11, 2022 | 11,220,546 | Anti-PD-L1 antibodies and uses thereof | Pharmaceuticals | I-MAB BIOPHARMA US LIMITED |
| Dec 28, 2021 | 11,208,486 | Human PD-L1 antibodies | Pharmaceuticals | I-MAB BIOPHARMA US LIMITED |
| Jul 13, 2021 | 11,059,897 | Anti-IFNAR1 antibodies for treating autoimmune diseases | Analysis of biological materials | I-MAB BIOPHARMA US LIMITED |
| Jun 15, 2021 | 11,034,771 | Anti-CD73 anti-PD-L1 bispecific antibodies | Biotechnology | I-MAB BIOPHARMA US LIMITED |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| May 22, 2025 | 2025/0163150 | COMBINATION THERAPIES COMPRISING A KRAS INHIBITOR FOR THE TREATMENT OF CANCER | Pharmaceuticals | I-MAB BIOPHARMA US LIMITED |
| May 8, 2025 | 2025/0145718 | ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF | Biotechnology | I-MAB BIOPHARMA US LIMITED |
| Dec 7, 2023 | 2023/0393144 | METHODS FOR MITIGATING INTERFERENCE BY THERAPEUTIC ANTI-CD47 ANTIBODIES IN PRE-TRANSFUSION ASSAYS | Analysis of biological materials | I-Mab Biopharma US Limited |
| Jun 8, 2023 | 2023/0174649 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES | Biotechnology | I-Mab Biopharma US Limited |
| Nov 3, 2022 | 2022/0348675 | ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF | Biotechnology | I-Mab Biopharma US Limited |
| Apr 21, 2022 | 2022/0119531 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF | Pharmaceuticals | I-Mab Biopharma US Limited |
| Apr 14, 2022 | 2022/0112258 | BIFUNCTIONAL MOLECULES WITH IL-7 ACTIVITY | Pharmaceuticals | I-Mab Biopharma US Limited |
| Oct 14, 2021 | 2021/0317224 | ANTI-CLAUDIN 18.2 AND ANTI-4-IBB BISPECIFIC ANTIBODIES AND USES THEREOF | Biotechnology | I-Mab Biopharma US Limited · patent 11,261,259 granted from it |
| Sep 16, 2021 | 2021/0284724 | ANTI-CXCL13 ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES AND CANCER | Pharmaceuticals | I-Mab Biopharma US Limited · patent 12,145,982 granted from it |
| Sep 2, 2021 | 2021/0269522 | Novel CD47 Antibodies and Methods of Using Same | Biotechnology | I-MAB BIOPHARMA US LIMITED |
What it applied for, 2024 to 2025: Biotechnology 1 · Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.